Delving into the Latest Updates on Rechon Life Science AB with Synapse

Overview

Tags

Immune System Diseases

Endocrinology and Metabolic Disease

Biosimilar

Hormone

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Biosimilar	1
Hormone	1

Top 5 Target	Count

INSR(Insulin receptor)	1

主要目的：就促卵泡激素（FSH）随时间变化的总暴露量和最大暴露量，证明贺美奇注射笔和贺美奇粉剂的生物等效性次要目的: 比较贺美奇注射笔和贺美奇粉剂的FSH、人绒毛膜促性腺激素（hCG）和黄体生成素（LH）的药代动力学（PK）参数比较贺美奇注射笔与贺美奇粉剂的安全性

[Translation]

Primary objective: To demonstrate the bioequivalence of the Hemeiqi Pen and Hemeiqi Powder in terms of total exposure and maximum exposure of follicle stimulating hormone (FSH) over time Secondary objective: To compare the pharmacokinetic (PK) parameters of FSH, human chorionic gonadotropin (hCG) and luteinizing hormone (LH) between the Hemeiqi Pen and Hemeiqi Powder To compare the safety of the Hemeiqi Pen and Hemeiqi Powder

Start Date02 Nov 2021

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

[+2]

EUCTR2016-004691-22-DE / Not yet recruitingPhase 3

A Randomised, Open, Parallel-group Phase III Biosimilarity Study to Assess the Long-term Safety, Focusing on Immunogenicity, of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.

Start Date21 Nov 2017

Sponsor / Collaborator

Rechon Life Science AB

100 Clinical Results associated with Rechon Life Science AB

Login to view more data

0 Patents (Medical) associated with Rechon Life Science AB

Login to view more data

100 Deals associated with Rechon Life Science AB

Login to view more data

100 Translational Medicine associated with Rechon Life Science AB

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human insulin biosimilar(Rechon Life Science AB) ( INSR )	Diabetes Mellitus, Type 1 More	Phase 3
Menotropins ( FSHR x LHCGR )	Infertility More	Pending